Non-profit website: free to use. No fees from patients, hospitals or doctors. Not an agency. · Free · Not an agencyAbout this site
Medical oncology · Peking University Cancer Hospital · Beijing

Dr. Liu Jiayong刘佳勇

Chief Physician · Associate Professor
Deputy department head

Summary compiled from public information, updated 18 Nov 2026. It has not been checked against the hospital website yet. Confirm details with the hospital before you travel.

Dr. Liu Jiayong

Professional overview

Dr. Liu Jiayong is a Chief Physician and Associate Professor at Peking University Cancer Hospital, specializing in the standardized and individualized management of soft tissue sarcomas and bone and soft tissue tumors, including surgical treatment, systemic therapy (chemotherapy, targeted therapy, immunotherapy), and melanoma surgery.

SpecialtyMedical oncology
Clinical titleChief Physician
Academic rolesAssociate Professor
DepartmentDepartment of Bone and Soft Tissue Tumors
HospitalPeking University Cancer Hospital
CityBeijing
Hospital roleDeputy Director, Department of Bone and Soft Tissue Tumors

Department leadership

Deputy department head

A department head is an organisational role. “Chief Physician” is a clinical rank; the two are listed separately.

Areas of focus

Soft tissue sarcomaSpecializes in standardized diagnosis and treatment and individualized systemic therapy including chemotherapy, targeted therapy, and immunotherapy.
Bone and soft tissue tumor surgeryPerforms surgical treatment of bone and soft tissue tumors, with 2 years of microsurgical training, particularly in vascular and neural preservation and soft tissue reconstruction during limb sarcoma resection.
Malignant melanomaPerforms surgical treatment of cutaneous malignant melanoma.

Background

  • 2010Translated and published the first Chinese edition of the NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma.
  • 2021Led clinical studies on anlotinib combined with PD-1 inhibitors for advanced soft tissue sarcoma and the ASPS expansion cohort, presented as poster presentations at ASCO and ESMO.
  • 2022Co-first author of a TCR-T clinical trial targeting NY-ESO, presented orally at ASCO.
  • 2024Led a clinical study presented orally at ASCO, plus three additional studies presented as posters.

Experience & recognition

  • Over 1,000 annual inpatient surgeries (including South Suburb Hospital)
  • Highest outpatient and surgical volume in the department for over ten consecutive years
  • First to perform TC99-Rituximab–guided sentinel lymph node biopsy for melanoma in China (2008)
  • Editorial Board Member of Chinese Journal of Cancer Prevention and Treatment (Youth Editor) and Electronic Journal of Comprehensive Cancer Therapy
  • Deputy Editor of Chinese Expert Consensus on Surgical Management of Cutaneous and Acral Malignant Melanoma
  • Principal Investigator of multiple clinical trials in soft tissue sarcoma
  • Published over ten papers as first or corresponding author in journals including Signal Transduction and Targeted Therapy, Cellular & Molecular Immunology, and Clinical Cancer Research, with cumulative impact factor over 200

Professional roles

  • Standing Committee Member, Bone and Soft Tissue Tumor Society, Chinese Medical Education Association
  • Standing Committee Member, Bone and Soft Tissue Tumor Committee, China Primary Health Care Foundation
  • Standing Committee Member, Melanoma Committee, Chinese Society of Clinical Oncology (CSCO)
  • Youth Vice Chair, Orthopedics Committee, China Health Industry Association
  • Member, Bone Tumor Study Group, Orthopedics Society, Chinese Medical Association
  • Member, Bone and Bone Metastasis Tumor Study Group, China Anti-Cancer Association (CACA)
  • Member, Soft Tissue Sarcoma Study Group, China Anti-Cancer Association (CACA)
  • Standing Committee Member, Skin Tumor Surgery Study Group, China Anti-Cancer Association (CACA)

Frequently asked questions

What does Dr. Liu Jiayong specialize in?

Specializes in standardized and individualized treatment of soft tissue sarcomas (e.g., undifferentiated pleomorphic sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, alveolar soft part sarcoma, epithelioid sarcoma, fibrosarcoma, angiosarcoma, desmoid tumor), surgical management of bone and soft tissue tumors, and surgical treatment of cutaneous malignant melanoma.

Which hospital and department is Dr. Liu Jiayong in?

Department of Bone and Soft Tissue Tumors at Peking University Cancer Hospital

Sources

Dr. Liu Jiayong has not reviewed this page.